Eli Lilly and Co at UBS Global Healthcare Conference (Virtual) Transcript

May 19, 2020 / 02:50PM GMT
Navin Cyriac Jacob - UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic

Hello, and welcome to day 2 of the UBS Global Healthcare Conference. My name is Navin Jacob. I'm the senior analyst covering large tech pharmaceuticals and smid-cap biotech. Our next presentation or fireside chat is with Eli Lilly. It's my pleasure to have with us Mike Mason, President of Lilly Diabetes, as well as Mike Czapar from the Investor Relations team. Mike and Mike, thank you so much for joining us today. Hope you're both well.

Michael B. Mason - Eli Lilly and Company - Senior VP & President of Lilly Diabetes

Thank you. Yes, we're both healthy and safe.

Questions and Answers:

Navin Cyriac Jacob - UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic

Fantastic. That's great to hear. And so why don't we start at a broad level with a topic that can't be escaped, obviously COVID-19. We'll start
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot